Hematologic Malignancy Clinical Trials

61 recruiting

Hematologic Malignancy Trials at a Glance

69 actively recruiting trials for hematologic malignancy are listed on ClinicalTrialsFinder across 6 cities in 21 countries. The largest study group is Not Applicable with 19 trials, with the heaviest enrollment activity in Boston, Memphis, and Philadelphia. Lead sponsors running hematologic malignancy studies include St. Jude Children's Research Hospital, Massachusetts General Hospital, and Duke University.

Browse hematologic malignancy trials by phase

Treatments under study

About Hematologic Malignancy Clinical Trials

Looking for clinical trials for Hematologic Malignancy? There are currently 61 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Hematologic Malignancy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Hematologic Malignancy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 69 trials

Recruiting
Not Applicable

Mindfulness Intervention for Sleep Disturbance and Symptom Management in Hematologic Cancer Patients During and After Inpatient Treatment

Hematologic Malignancy
Duke University60 enrolled1 locationNCT06532773
Recruiting
Not Applicable

Feasibility and Acceptability of Primary Palliative Care Intervention in Patients Undergoing Hematopoietic Stem Cell Transplantation

Hematologic MalignancyHematopoietic Cell Transplant
Massachusetts General Hospital40 enrolled1 locationNCT06676852
Recruiting
Not Applicable

Allergy Delabeling in Antibiotic Stewardship - Intervention

Hematologic MalignancyBeta Lactam Allergy
Ebbing Lautenbach3,800 enrolled1 locationNCT07133074
Recruiting
Not Applicable

Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy

Multiple MyelomaLymphomaLeukemia+2 more
Massachusetts General Hospital90 enrolled1 locationNCT05646576
Recruiting
Phase 1Phase 2

CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)

Relapsed Hematologic MalignancyRefractory Hematologic MalignancyRelapsed Primary Central Nervous System Lymphoma+1 more
Curis, Inc.152 enrolled45 locationsNCT03328078
Recruiting

Reduced Intensity Fludarabine and TBI Prior to Haplo-Identical Transplantation

Hematologic Malignancy
Northside Hospital, Inc.20 enrolled1 locationNCT05417971
Recruiting
Phase 2

GM-CSF With Post-Transplant Cyclophosphamide

Transplant-Related Hematologic Malignancy
Northside Hospital, Inc.38 enrolled1 locationNCT04237623
Recruiting
Phase 1

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Acute Myeloid LeukemiaAcute LeukemiaAML+9 more
Kura Oncology, Inc.171 enrolled45 locationsNCT06001788
Recruiting
Phase 1

CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma

Hematologic MalignancyRelapsed Pediatric ALLHematopoietic Cell Transplantation
St. Jude Children's Research Hospital60 enrolled1 locationNCT07257419
Recruiting
Phase 3

Comparing the Efficacy of Different Durations of Maribavir Treatment Regimens in Allo-HSCT

Hematologic Malignancy
Ruijin Hospital218 enrolled1 locationNCT07511127
Recruiting
Phase 2

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Acute Lymphoblastic LeukemiaAcute Myeloid LeukemiaAcute Leukemia+21 more
Masonic Cancer Center, University of Minnesota70 enrolled1 locationNCT05735717
Recruiting

Prospective Evaluation Of Delayed Effects Of Pediatric Car T Cell Therapy

Solid TumorHematologic MalignancyB-ALL
St. Jude Children's Research Hospital100 enrolled3 locationsNCT06579469
Recruiting
Not Applicable

ONC-MM-2407: The Effect of Virtual Reality Headsets on Pain and Anxiety in the Peri and Post Bone Marrow Biopsy Period

Hematologic Malignancy
Wake Forest University Health Sciences160 enrolled1 locationNCT07203534
Recruiting

Novel 3D Hematological Malignancy Organoid to Study Disease Biology and Chemosensitivity

Hematologic Malignancy
Wake Forest University Health Sciences70 enrolled1 locationNCT03890614
Recruiting

Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplant

LymphomaLeukemiaHematologic Malignancy
National Cancer Institute (NCI)88 enrolled1 locationNCT06856226
Recruiting
Phase 1

Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients With Relapsed Hematologic Cancers Undergoing a Second Donor Stem Cell Transplant

Recurrent Adult Acute Myeloid LeukemiaPreviously Treated Myelodysplastic SyndromeRecurrent Adult Acute Lymphoblastic Leukemia+1 more
University of Chicago30 enrolled1 locationNCT02333162
Recruiting
Phase 1

Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies

Acute Myeloid LeukemiaHematologic MalignancyMyelodysplastic Syndromes+1 more
University of Alabama at Birmingham20 enrolled1 locationNCT07044544
Recruiting
Phase 1

Feasibility and Safety of Collecting and Combining Autologous Hematopoietic Stem Cells With Chimeric Antigen Receptor (CAR) T-Cell Therapy in Subjects With Relapsed/Refractory Hematological Malignancies

Diffuse Large B Cell LymphomaAcute Lymphoblastic LeukemiaMultiple Myeloma+3 more
Joshua Sasine, MD, PhD20 enrolled1 locationNCT05887167
Recruiting

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

LymphomaAMLLeukemia+7 more
Children's Hospital Medical Center, Cincinnati30 enrolled5 locationsNCT06131801
Recruiting
Phase 2

Study of Posaconazole Prophylaxis in Patients Receiving Hematopoietic Stem Cell Allograft (Allo-HSC) at High Risk of Invasive Fungal Infection (IFI)

Hematologic Malignancy
Nantes University Hospital30 enrolled1 locationNCT06541067